Lv1
70 积分 2024-04-01 加入
Model‐Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti–Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn Disease
3小时前
已完结
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?
2个月前
已完结
Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
2个月前
已完结
皖公网安备34019202002308
